Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|11|1|62-68

ISSN： 1574-8863

Source： Current Drug Safety, Vol.11, Iss.1, 2016-03, pp. : 62-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 271-277

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 92, Iss. 5, 2017-02 ,pp. : 283-290

Karger

Access to resources Recommend Favorite

Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer

By  

HISTOPATHOLOGY, Vol. 72, Iss. 3, 2018-02 ,pp. : 449-459

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chemotherapy in Elderly Patients with Advanced Lung Cancer Part II: Treatment of Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 27, Iss. 6, 2004-12 ,pp. : 583-588

Karger

Access to resources Recommend Favorite

Targeted therapy in lung cancer

By  

RESPIROLOGY (ELECTRONIC), Vol. 20, Iss. 3, 2015-04 ,pp. : 370-378

John Wiley & Sons Inc

Access to resources Recommend Favorite